Surely You Joust
Executive SummaryChiron's and Roche's press releases announcing a decision by the European Patent Office's Technical Board of Appeals regarding HCV patents made it sound like the companies were attending different hearings and discussing different subject matter. They epitomize the brinksmanship the two are playing over the nucleic acid testing (NAT) market.
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.